Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 120 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
- The report reviews Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Overview 10
Therapeutics Development 11
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Stage of Development 11
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Therapy Area 12
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Indication 13
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Companies 17
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Universities/Institutes 21
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development 30
Amgen Inc. 30
Antisense Therapeutics Limited 31
Astellas Pharma Inc. 32
AstraZeneca Plc 33
Axelar AB 34
Boehringer Ingelheim GmbH 35
Bristol-Myers Squibb Company 36
Eli Lilly and Company 37
F. Hoffmann-La Roche Ltd. 38
Genmab A/S 39
Immunomedics, Inc. 40
Insmed Incorporated 41
Merck & Co., Inc. 42
Merrimack Pharmaceuticals, Inc. 43
Novartis AG 44
PharmAbcine, Inc. 45
ProteoThera, Inc. 46
Silver Creek Pharmaceuticals, Inc. 47
Sucampo Pharmaceuticals, Inc. 48
TyrNovo Ltd. 49
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Drug Profiles 50
1R-15-15 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
1R-3s - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
1R-E1-E1 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ATL-1101 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
AXL-1717 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
AZD-3463 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
BI-893923 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
BMS-754807 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
CT-707 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
dalotuzumab - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
ganitumab - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
lenaldekar - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
linsitinib - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
M-590 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
mecasermin rinfabate (recombinant) - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
MM-141 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Monoclonal Antibody to Antagonize IGFR-1 for Oncology and Inflammatory Disorders - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
NT-219 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Recombinant Protein to Agonize Insulin Like Growth Factor 1 Receptor for Phelan-McDermid Syndrome - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
RU-105 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Small Molecule to Antagonize IGF-1R for Oncology - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Small Molecules to Inhibit IGF-1R for Oncology - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Small Molecules to Inhibit IGF-1R/IR for Oncology - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
teprotumumab - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Vaccine to Target HER-2, IGFBP-2 and IGF1R for Breast Cancer - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
vesiculin - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
XGFR-2 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
XGFR-4 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Dormant Projects 96
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Discontinued Products 103
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Featured News & Press Releases 108
Jul 29, 2015: CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave's Orbitopathy 108
May 05, 2015: Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 108
Apr 21, 2015: First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 109
Mar 17, 2015: Study suggests precision medicine for adrenal cancer 110
Jan 20, 2015: Merrimack Pharmaceuticals Presents First-in-human study of MM-141 at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 111
Nov 05, 2014: FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals MM-141 for the Treatment of Pancreatic Cancer 112
Jun 02, 2014: Merrimack Pharmaceuticals Presents Phase 1 Clinical Data From MM-141 at the 2014 ASCO Annual Meeting 113
Feb 18, 2014: Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics 113
Jan 14, 2014: AmorChem Invests In A Potential Therapy For Late-Stage Breast Cancer 114
Dec 27, 2013: Axelar announces final data from Phase II study with AXL1717 in lung cancer 115
Oct 15, 2013: Merrimack Pharmaceuticals to Present Preclinical Data On MM-141 at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 116
Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease 116
Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy 116
Apr 02, 2013: Axelar Announces Preliminary Results From Phase II Study Demonstrating Efficacy Of AXL1717 In Non-Small Cell Lung Cancer Patients 117
Jan 21, 2013: Axelar Initiates Phase I/II Study Of AXL1717 In Patients With Malignant Astrocytomas In US 117
Appendix 119
Methodology 119
Coverage 119
Secondary Research 119
Primary Research 119
Expert Panel Validation 119
Contact Us 119
Disclaimer 120

List of Tables

Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Development by Companies, H1 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2016 21
Products under Investigation by Universities/Institutes, H1 2016 22
Assessment by Monotherapy/Combination Products, H1 2016 23
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Pipeline by Amgen Inc., H1 2016 30
Pipeline by Antisense Therapeutics Limited, H1 2016 31
Pipeline by Astellas Pharma Inc., H1 2016 32
Pipeline by AstraZeneca Plc, H1 2016 33
Pipeline by Axelar AB, H1 2016 34
Pipeline by Boehringer Ingelheim GmbH, H1 2016 35
Pipeline by Bristol-Myers Squibb Company, H1 2016 36
Pipeline by Eli Lilly and Company, H1 2016 37
Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 38
Pipeline by Genmab A/S, H1 2016 39
Pipeline by Immunomedics, Inc., H1 2016 40
Pipeline by Insmed Incorporated, H1 2016 41
Pipeline by Merck & Co., Inc., H1 2016 42
Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 43
Pipeline by Novartis AG, H1 2016 44
Pipeline by PharmAbcine, Inc., H1 2016 45
Pipeline by ProteoThera, Inc., H1 2016 46
Pipeline by Silver Creek Pharmaceuticals, Inc., H1 2016 47
Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 48
Pipeline by TyrNovo Ltd., H1 2016 49
Dormant Projects, H1 2016 96
Dormant Projects (Contd..1), H1 2016 97
Dormant Projects (Contd..2), H1 2016 98
Dormant Projects (Contd..3), H1 2016 99
Dormant Projects (Contd..4), H1 2016 100
Dormant Projects (Contd..5), H1 2016 101
Dormant Projects (Contd..6), H1 2016 102
Discontinued Products, H1 2016 103
Discontinued Products (Contd..1), H1 2016 104
Discontinued Products (Contd..2), H1 2016 105
Discontinued Products (Contd..3), H1 2016 106
Discontinued Products (Contd..4), H1 2016 107